Ad
related to: repatha and bowel issues in adults causes and signs pictures and treatmentgoodrx.com has been visited by 100K+ users in the past month
"This free app will find the best local deals." - AOL.com
Search results
Results from the WOW.Com Content Network
Evolocumab, [6] sold under the brand name Repatha, is a monoclonal antibody that is an immunotherapy medication for the treatment of hyperlipidemia. Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) .
Possible causes include exocrine pancreatic insufficiency, with poor digestion from lack of lipases, loss of bile salts, which reduces micelle formation, and small intestinal disease-producing malabsorption. Various other causes include certain medicines that block fat absorption or indigestible or excess oil/fat in diet.
Repatha is a brand name for the injectable drug evolocumab. Repatha treats high cholesterol and reduces the risk of heart attack , stroke, and certain types of heart surgery in adults with ...
Bile acid malabsorption (BAM), known also as bile acid diarrhea, is a cause of several gut-related problems, the main one being chronic diarrhea.It has also been called bile acid-induced diarrhea, cholerheic or choleretic enteropathy, bile salt diarrhea or bile salt malabsorption.
Tenesmus is characterized by a sensation of needing to pass stool, accompanied by pain, cramping, and straining. Despite straining, little stool is passed. [3] Tenesmus is generally associated with inflammatory diseases of the bowel, which may be caused by either infectious or noninfectious conditions.
External signs and symptoms are constipation of very long duration, [2] abdominal bloating, abdominal tenderness and tympany, abdominal pain, palpation of hard fecal masses and, in toxic megacolon, fever, low blood potassium, tachycardia and may lead to shock.
The latest approval comes after a setback in April, when The U.S. Food and Drug Administration (FDA) had declined clearance citing issues related to the proposed manufacturing of the treatment.
Treatment is by normalization of bowel habits, biofeedback, and other conservative measures. In more severe cases various surgical procedures may be indicated. The condition is relatively rare, affecting approximately 1 in 100,000 people per year. It affects mainly adults aged 30–50. Females are affected slightly more often than males.